1071P Phase III, randomized, double-blind, placebo (Pbo)-controlled ENGOT-ov43/GOG-3036/KEYLYNK-001 study of 1L chemotherapy (CT) ± pembrolizumab (pembro) then maintenance (Maint) pembro ± olaparib (Ola) for advanced BRCA-nonmutated epithelial ovarian cancer (EOC): Analysis by HRD status | Publicación